The intervention being tested is BNT327, administered in two dose levels, combined with standard chemotherapy drugs such as etoposide, carboplatin, paclitaxel, and topotecan. The purpose is to ...

BioNTech SE is currently sponsoring a clinical study titled ‘A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

Key Takeaways BioNTech and Bristol Myers Squibb have entered a major global collaboration to co-develop and co-commercialize BNT327, a bispecific antibody for solid tumors, with $1.5B upfront, $2 ...

This trial is comparing BNT327 and standard chemotherapy with atezolizumab and standard chemotherapy. It is for people having their first treatment for small cell lung cancer that has spread within ...

Doctors are looking for ways to improve treatment for NSCLC. In this trial, they are looking at an experimental drug called BNT327. It is a new type of immunotherapy drug . It works in 2 ways. It aims ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific antibody BNT327.

BNT327/PM8002 is designed to restore effector T-cell function by binding to PD-L1, as well as localize VEGF-A neutralization within the tumor microenvironment, therefore reversing the dampening of ...

Today, we announced a global strategic partnership with BioNTech SE to co-develop and co-commercialize BNT327, an investigational, next-generation PD-L1/VEGF bispecific antibody being studied ...

Today we announce a global 50/50 strategic collaboration with BMS to jointly develop and commercialise BNT327, our anti-PDL1xVEGF antibody. Joining forces with BMS will enable us to broaden our ...

BioNTech's BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date.

Newman’s confidence in BNT327’s prospects justifies his Buy rating on BioNTech SE’s stock. Newman covers the Healthcare sector, focusing on stocks such as Merus, Regeneron, and BioNTech SE.